Summary of investigation findings on admission and after the onset of tachycardia
| Investigation (units) | Normal range | On admission | Onset of tachycardia |
| LDH (U/L) | 222–454 | 433 | 440 |
| CK (U/L) | 56–336 | – | 45 |
| CKMB (μg/L) | 1.0–5.0 | – | <1 |
| Trop (ng/L) | <30 | <13 | <13 |
| Ur (mmol/L) | 2.7–6.9 | 3.7 | 3.6 |
| Na (mmol/L) | 136–146 | 133 | 138 |
| K (mmol/L) | 3.6–5.0 | 4.4 | 4.7 |
| Cl (mmol/L) | 100–107 | 100 | 100 |
| HCO3 (mmol/L) | 19.0–29.0 | 22.6 | 27.3 |
| Cr (μmol/L) | 54–101 | 73 | 72 |
| Alb (g/L) | 40–51 | –— | 38 |
| Bili (μmol/L) | 7–32 | – | 19 |
| ALP (U/L) | 39–99 | – | 218 |
| ALT (U/L) | 6–66 | – | 77 |
| AST (U/L) | 12–42 | – | 44 |
| GGT (U/L) | 19–94 | – | 234 |
| CRP (mg/L) | 0.2–9.1 | 11.3 | 122 |
| Procal (UG/L) | <0.50 | – | 0.13 |
| Hb (G/DL) | 14.0–18.0 | 14.3 | 13.7 |
| WCC (×109/L) | 4.0–10.0 | 9.6 | 11.56 |
| Plt (×109/L) | 140–440 | 444 | 592 |
| Free T4 (pmol/L) | 8.8–14.4 | – | 41.8 |
| Free T3 (pmol/L) | 3.2–5.3 | – | 13.4 |
| TSH (μ/L) | 0.65–3.70 | – | <0.01 |
| TRAb (IU/L) | <1.76 | – | <1.10 (negative) |
| TPOAb (IU/ML) | <9.0 | – | 2.0 (negative) |
| COVID-19 | – | Detected | – |
Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Bili, bilirubin; CK, creatinine kinase; CKMB, creatinine kinase myocardial band; Cr, creatinine; CRP, C reactive protein; GGT, gamma-glutamyl transferase; Hb, haemoglobin; HCO3, bicarbonate; K, potassium; LDH, lactate dehydrogenase; Na, sodium; Plt, platelet; Procal, procalcitonin; T3, thyroxine 3; T4, thyroxine 4; TPOAb, thyroid peroxidase antibody; TRAb, thyrotropin receptor antibody; Trop, troponin; TSH, thyroid-stimulating hormone; Ur, urea; WCC, white cell count.